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Mesenchymal stem cell
TGF-βTransplantation of mesenchymal stem cells (MSCs) has been shown to enhance the recovery of brain func-
tions following ischemic injury. Although immune modulation has been suggested to be one of the mecha-
nisms, the molecular mechanisms underlying improved recovery has not been clearly identiﬁed. Here, we
report that MSCs secrete transforming growth factor-beta (TGF-β) to suppress immune propagation in the
ischemic rat brain. Ischemic stroke caused global death of resident cells in the infarcted area, elevated the
monocyte chemoattractant protein-1 (MCP-1) level, and evoked massive inﬁltration of circulating CD68+
immune cells through the impaired blood–brain barrier. Transplantation of MSCs at day 3 post-ischemia
blocked the subsequent upregulation of MCP-1 in the ischemic area and the inﬁltration of additional
CD68+ immune cells. MSC-conditioned media decreased the migration and MCP-1 production of freshly iso-
lated immune cells in vitro, and this effect was blocked by an inhibitor of TGF-β signaling or an anti-TGF-β
neutralizing antibody. Finally, transplantation of TGF-β1-silenced MSCs failed to attenuate the inﬁltration
of CD68+ cells into the ischemic brain, and was associated with only minor improvements in motor function.
These results indicate that TGF-β is key to the ability of MSCs to beneﬁcially attenuate immune reactions in
the ischemic brain. Our ﬁndings offer insight into the interactions between allogeneic MSCs and the host im-
mune system, reinforcing the prospective clinical value of using MSCs in the treatment of neurological disor-
ders involving inﬂammation-mediated secondary damage.
© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-SA license. Introduction
Mesenchymal stem cells (MSCs) are multipotent stem cells that
can be isolated from various tissues including bone marrow, adipose
tissue, and umbilical cord blood (Kern et al., 2006; Pittenger et al.,
1999; Wagner et al., 2005). MSCs have been administered to patientsRegulating Biodrug, Ajou Uni-
eongtong-gu, Suwon 443-721,
atomy, Ajou University School
uwon 443-721, South Korea.
suh@ajou.ac.kr (H. Suh-Kim).
irect.com).
nc.Open access under CC BY-NC-SA licwith diverse neurological diseases, including ischemic stroke (Parr et
al., 2007). Despite their potential to differentiate into adipocytes, os-
teocytes and chondrocytes, ex vivo cultured autologous MSCs are
safe when injected intravenously in stroke patients, and the grafted
groups showed higher frequencies of functional recovery (Honmou
et al., 2011; Li et al., 2008). Additional clinical studies are currently
ongoing or planned (http://www.clinicaltrials.gov), making it increas-
ingly important to use preclinical animal studies to understand the bio-
logical mechanisms underlying MSC-mediated tissue restoration.
Ischemic stroke impairs cellular energy metabolism, leading to fail-
ure of the energy-dependent processes necessary for cell survival.
Brain cells undergo cell death and release their cytoplasmic contents
into the extracellular space, evoking inﬂammatory cascades and ampli-
fying the tissue damage. Reactive macrophages and leukocytes are
recruited into ischemic regions, where they cooperate with resident
neurons, astrocytes, andmicroglia to generate proinﬂammatorymedia-
tors; these include enzymes, such as inducible nitric oxide synthase
(iNOS) and cyclooxygenase-1(COX-2), as well as cytokines and
chemokines, such as interleukin-1 (IL-1), IL-6, IL-8, tumor necrosisense. 
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(Lakhan et al., 2009). Together, these inﬂammatory mediators increase
the permeability of the blood–brain barrier (BBB), provoking a massive
invasion of peripheral immune cells and causing inﬂammatory cascades
that further amplify tissue damage (Pan and Kastin, 2007).
Preclinical studies by our group and others have indicated thatMSCs
exert pleiotropic inﬂuences in rodent stroke models (Castellanos and
Serena, 2007; Chopp and Li, 2002; Lee et al., 2008; Yoo et al., 2008).
MSCs have been shown to increase host cell survival, promote the pro-
liferation of endogenous neural progenitor cells in the neurogenic
niche, and reduce brain inﬂammation. However, although numerous
studies have suggested that the beneﬁcial effects of MSCs are mediated
by trophic factors and cytokines (Parr et al., 2007), the underlying mo-
lecular mechanisms have not yet been clariﬁed.
In this study, we demonstrate that MSC-generated TGF-β is a key
player in suppressing immune propagation during the delayed period
post-ischemia. We demonstrate that ischemic damage-induced
MCP-1 expression causes peripheral immune cells to inﬁltrate
through the impaired BBB, but MSC-secreted TGF-β decreases the
production of MCP-1 in immune cells and blocks the subsequent mi-
gration of additional immune cells. In contrast, TGF-β-knockdown
MSCs fail to block immune responses, leading to poor recovery in a
rat stroke model. This study provides preclinical evidence that
TGF-β may be a key molecule governing the beneﬁcial effects of
MSCs in stroke patients.
Materials and methods
Cell culture
All experimental protocols using MSCs were approved by the Insti-
tutional Review Board of the Ajou University Medical Center (Suwon,
South Korea). Human MSCs were isolated from bone marrow aspirates
and cultured in vitro, as previously described (Kim et al., 2005). Cul-
tured MSCs were positive for surface antigens STRO-1, CD29, CD49a,
CD73, CD90, and CD105 and were negative for HLA-DR, CD45, CD34,
CD11b, and CD117 and displayed the capacity for multi-lineage differ-
entiation into adipocytes, osteoblasts, and chondrocytes (Sung Park et
al., 2013). MSCs at passages 4–6 were used in this study.
Induction of MCAo, transplantation of MSCs, and measurement of infarct
volume
All animal protocols were approved by the Institutional Animal Care
and Use Committee of the Ajou University Medical School. Adult male
Sprague–Dawley rats weighing 250–270 g were utilized. Transient
middle cerebral artery occlusion (MCAo) was induced for 2 h by intro-
ducing a 4–0 monoﬁlament nylon suture with a rounded tip into the
common carotid artery (CCA) lumen until it blocked the bifurcating or-
igin of the MCA, as previously described (Kim et al., 2008). Animals
showing similar behavioral symptoms and comparable infarct volumes
(testedwithMRI at day 2) were selected and randomly grouped. At day
3, 5.0 × 105 of MSCs orMSCs/shTGF-β1 in 7 μl of PBSwere injected into
the striatum (AP, 0.5; ML, 2.5; DV, 5.0) and cortex (AP, — 0.5; ML, 2.0;
DV, 2.5) in the penumbra ipsilateral to the injury; the injection was
performed over 10 min with the aid of a stereotactic apparatus. A
total of 86 rats were used in this study, including those in the
sham-operated group (n = 11), PBS group (n = 18), MSC group
(n = 18), MSC/shTGF-β1 group (n = 15) and MCAo-only group
(n = 24) (Supplementary Table S1). The ischemic area from each
T2-weighted image was manually marked, and the infarct volume
was calculated as previously described (Kim et al., 2008). Independent
investigators were double-blinded to the animal's pre- and post-
transplant status to avoid subjective bias in all experiments. Additional-
ly, independent investigators were blinded to the assessment of infarct
volumes.Validation of BBB breakdown
Animals were injected with 4 ml/kg of 2% Evans blue dye
(Sigma-Aldrich Corporation, St. Louis, MO) in normal saline through
the tail vein (n = 3 per group) and intracardially perfused with PBS
and 4% paraformaldehyde (PFA) 4 h later. The brains were isolated
and photographed.
Immunohistochemical analysis
For immunohistochemistry, animals were intracardially perfused
with PBS and then ﬁxed with 4% PFA at the indicated times after re-
perfusion. Brains were embedded in parafﬁn and sectioned to 5-μm
thickness. Antigens were retrieved by boiling in 10 mM sodium cit-
rate (pH 6.0) in a microwave oven, the sections were blocked in
PBS with 1% bovine serum albumin and 5% normal serum, and
probed with primary antibodies against ionized calcium binding
protein-1 (Iba1, rabbit, 1:500; Sigma-Aldrich Corporation), CD68
(mouse, 1:200; Serotech, Kidlington, UK), myeloperoxidase (MPO,
rabbit, 1:100; Abcam, Cambridge, UK) and MCP-1 (rabbit, 1:100;
Novus Biologicals, Littleton, CO). The sections were then incubated
with Alexa Fluor 488- or -594-conjugated anti-IgG secondary anti-
bodies (Molecular Probes, Eugene, OR) and counterstained with
Hoechst 33258 (Molecular Probes). For measurement of microglial
death, the sections were subjected to staining with an in situ cell
death detection kit (Roche Diagnostics GmbH, Mannheim, Germany),
and ﬂuorescent images were acquired using a Zeiss LSM510 confocal
microscope (Carl Zeiss AG, Jena, Germany). Alternatively, the sections
were incubated with a biotin-conjugated secondary antibody (1:500)
and an avidin–biotin complex, using an ABC kit (Vector Laboratories,
Inc., Burlingame, CA) according to the manufacturer's protocol.
Bright-ﬁeld images were acquired using a Zeiss Axiophot microscope
(Zeiss).
Quantiﬁcation
Four 5-μm-thick coronal sections spaced 400 μm apart from the is-
chemic central region (AP, + 1.2 mm to−0.8 mm based on bregma)
were prepared from ﬁve animals per group. Light microscopic images
were acquired using a ScanScope CS digital slide scanner (Aperio,
Vista, CA), and the total number of immunoreactive cells in the ische-
mic penumbra were calculated using the Quantity One image analysis
software (Bio-Rad Laboratories, San Diego, CA). To measure the num-
ber of CD68+/MCP-1+ cells in ischemic penumbra regions, ﬁve con-
focal images were generated for each of the four sections, and the
immunoreactive cells that had distinct Hoechst-positive nuclei were
counted using NIH imaging software (ImageJ, http://rsbweb.nih.gov/
ij). Independent investigators were blinded to the counting of im-
mune positive cells. The results from the ﬁve animals are presented
as mean ± SD.
In vitro transwell migration assay
To induce enrichment of macrophages, 10 ml of 10% thioglycollate
(Sigma-Aldrich Corporation) was injected into the peritoneal cavities
of Sprague–Dawley rats. Four days later, immune cells were harvested
from the peritoneal cavity and red blood cells were removed with he-
molysis buffer (Invitrogen, Grand Island, NY). Peritoneal immune cells
(1 × 105 cells) were suspended in 300 μl DMEM and plated in the
upper chamber of a transwell apparatus (pore size, 8 μm; Corning
Costar, Corning Inc., NY). The lower chamber was loaded with 600 μl
DMEM, 100 μg/ml of brain ischemic extract (IE), and 100 ng/ml of re-
combinant MCP-1 (R&D Systems, Minneapolis, MN), 1 μg/ml of
anti-MCP-1 neutralizing antibody (R&D Systems), or 1 × 105 MSCs.
For preparation of IE, the ipsilateral hemisphere of day-3 ischemic
brain was homogenized in PBS and centrifuged at 12,000 ×g, and the
Fig. 1. Inﬂammatory responses in the ischemic brain. (A) BBB breakdown was determined with Evans blue dye. Leakage of the dye was detected at the occlusion point on day 1
(arrows). (B) Iba1+ or CD68+ cells in the penumbra are shown at various time points. CD68+ cells were not found in sham-operated rats. (C) Confocal images show that
round-shaped CD68+ cells (green) colocalized with Iba1+ cells (red) in each indicated region of ischemic hemisphere. COR, ischemic core, PE, ischemic penumbra. (D) Microglial
cell death was determined by double staining of TUNEL (green) and Iba1 (red) in the ischemic penumbra region (arrows). TUNEL+ nuclei were observed being phagocytosed by
Iba1+ cells (arrowhead). Scale bars in (B)–(D) = 10 μm.
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for 4 h at 37 °C in 5% CO2, the cells adhering to the upper side of the
membrane were removed with a cotton swab, and transmigrated cells
at the bottom side of the membrane were visualized by cresyl violet
or Hoechst dye staining. The average cell number from four random
ﬁelds of view was calculated from each well. The results from three in-
dependent experiments are presented as mean ± SD.
Knockdown of TGF-β1 with shRNA
To produce a lentiviral vector encoding a short hairpin RNA for
TGF-β1 (Lentilox-shTGF-β1), a double-stranded DNA (5′-TCAAT
TCCTGGCGATACCTCAGCAACTCTCGTTGCTGAGGTATCGCCAGGAATTGT-
TTTTTC-3) was inserted into pLentilox 3.7 (Addgene, Cambridge, MA).
The resulting pLentilox-shTGF-β1 was cotransfected into 293 T
cells along with pCMV-VSV-G and pCMVd8.9 (Addgene). Virus-
containing media were collected 48 h after transfection and ﬁltered
through a 0.45-μm ﬁlter. MSCs were transduced with Lentilox-
shTGF-β1 at 10 MOI and sorted with Lentilox-shTGF-β1. The
resulting cells (MSC/shTGF-β1) were enriched for GFP expression
using BS FACSAria III (BD Biosciences, San Jose, CA). Knockdown of
TGF-β1 expression was veriﬁed by measurement of the level of se-
creted TGF-β1 (Supplementary Fig. S1). Finally, the TGF-β1-
knockdown cells were expanded in growth medium and used for
transplantation.
RNA isolation and RT-PCR
The ischemic penumbra region at day 4 (9.0 mm3, 1.0 ×
1.5 × 6.0 mm) was dissected from AP, 0.5 mm to AP, -0.5 mm(Supplementary Fig. S2) and total RNA was isolated using RNAzol B
(Tel-Test Inc., Friendswood, TX) according to the manufacturer's proto-
col. Peritoneal immune cells were isolated as described above and plat-
ed in 60-mm culture dishes at a density of 1.0 × 105 cells/well. Cells
were allowed to adhere to the plates, and unattached cells were re-
moved 3 h later. MSC or NIH3T3 cell cultures were grown in DMEM
containing 10% FBS, 1% penicillin and streptomycin for 2 days, and
mediawere collected and ﬁltered through a 0.2-μmﬁlter. Peritoneal im-
mune cells were treated with the ﬁltrates with or without recombinant
human TGF-β1 (20 ng/ml, rTGF-β1; Millipore, Billerica, MA), TGF-β re-
ceptor I kinase [3-(pyridine-2yl)-4-(quinonyl)]-1H-pyrazone (100 nM,
TGF-β-RI; Millipore), or anti-TGF-β1-neutralizing antibody (1 μg/ml;
R&D Systems). After 10 min, 100 μg/ml ischemic extract (IE) was
added. Six hours after treatment, total RNA was isolated and 1 μg of
RNA was reverse transcribed in a 20-μl reaction using a 1st Strand
cDNA synthesis kit (Roche Diagnostics). PCR analysis was carried out
on 1 μl of the ﬁrst-strand cDNA (primer sequences and PCR conditions
are summarized in Supplementary Table S2). The products were
subjected to semi-quantitative analysis using the Quantity One image
analysis software (Bio-Rad Laboratories).Statistics
Results were analyzed using one-way or repeatedmeasures ANOVA
with treatment groups and days of testing as the independent variables,
followed by Scheffe's post-hoc test for multiple comparisons by mea-
surement day. Student's t-tests were used to analyze between-group
differences in mRNA expression and in vitro transwell migration. The
level of statistical signiﬁcance was set at p b 0.05. All values are
presented as the mean ± SD.
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Inﬂammatory responses in the ischemic brain
To assess immune responses in the ischemic brain, we determined
when the BBB started to disintegrate under our experimental conditions.
We injected Evans blue dye into the tail veins of ischemic animals at var-
ious time points after induction of ischemia and sacriﬁced the animals
4 h later. The leakage of Evans blue dye was found speciﬁcally near the
occlusion point (i.e., the branching point of the MCA and anterior cere-
bral artery) as early as post-ischemic day 1, but progressively spread
out to the entire hemisphere betweenday 3 andday 7 (Fig. 1A). Concom-
itantly, the number of CD68+ cells with amoeboid morphologies and
thick processes increased massively in the ischemic region between
day 3 and day 7 (Fig. 1B). These cells were not found in the
sham-operated animals, where the resident microglia were Iba1+ cells
with ramiﬁed morphology and branched processes. In the ischemic
brain, CD68-immunoreactivity colocalized with Iba1+ cells (Fig. 1C),
suggesting that most of the CD68+ cells with amoeboid morphology
emerging from day 1 were phagocytic cells, such as activated microglia
and/or inﬁltrating peripheral immune cells. However, TUNEL+ assays
indicated that a majority of the Iba1+ cells were undergoing cell death
in the ischemic region at day 1 (arrows in Fig. 1D). Furthermore, between
days 3 and 7, TUNEL+ nuclei (arrowheads) appeared to be adjacent to
round-shaped Iba1+ cells, as if the dying cells had been engulfed by
phagocytic Iba1+ cells. Notably, the emergence rates of round-shaped
Iba1+ or CD68+ cells correlated well with the extent of BBB breakageFig. 2.MSCs attenuate the inﬁltration of immune cells. (A) Recruitment of CD68+ immune c
ischemic penumbra region shown in (A). Note that MCP-1+ cells did not increase in animals
of positive cells per mm2 ± SD (ANOVA, **, p b 0.01). (C) Confocal images showing the M
expressed MCP-1 (arrows). In the MSC-treated group, most CD68+ cells failed to expressbetween days 3 and 7. Collectively, these data suggest that, similar to
neuronal and glial cells, most resident Iba1+ microglia in the ischemic
area undergo cell death. Furthermore, the Iba1+/CD68+ cells those
repopulate the area between days 3 and 7 appear to be phagocytic mac-
rophages that mobilize from the blood circulation through the impaired
BBB.
To further verify the peripheral origin of CD68+ cells, we freshly
isolated immune cells from the peritoneal cavity of GFP-expressing
transgenic rats (Supplementary Fig. S3A) and injected 5 × 106 cells
through the tail veins of MCAo-induced ischemic rats at day 1.
When the animals were sacriﬁced at day 3, transplanted GFP+ cells
were found in the ischemic region, where they constituted up to
24% of the total CD68+ cells (Supplementary Fig. S3B).
Although it was not practical to measure the total number of
CD68+ cells in the entire body, the observed migration of substantial
numbers of exogenous GFP+ immune cells to the ischemic area
reinforced our hypothesis that the majority of CD68+ inﬂammatory
cells found between days 3 and 7 represent monocytes/macrophages
recruited from the peripheral blood.
MCP-1 as a cytokine responsible for recruiting peripheral immune cells
Transplantation of MSCs in the ischemic penumbra at day 3 dramat-
ically inhibited the massive inﬁltration of CD68+ cells. Between days 4
and 7, the total number of CD68+ cells dramatically increased (by
4.7-fold) in the PBS-injected control group, whereas it increased by
only 2.2-fold in the MSC-injected group (Figs. 2A, B). Transplantationells to the ischemic penumbra. (B) Quantitative analysis of confocal images per mm2 of
subjected to MSC transplantation on day 3. The data are presented as the mean number
CP-1 expression (green) in CD68+ cells (red). In the PBS-treated group, CD68+ cells
MCP-1 (arrowheads). Scale bars in (A) and (C) = 10 μm.
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D). These results suggest that MSCs may directly downregulate the ex-
pression of MCP-1 in the CD68+ immune cells that moved into the is-
chemic region prior to MSC transplantation, thereby decreasing the
subsequent inﬁltration of additional CD68+ immune cells.
Indeed, RT-PCR analysis of mRNA indicated that the expression of
a variety of proinﬂammatory cytokines and signaling molecules, in-
cluding iNOS, TNF-α, IL-1β and MCP-1, were enhanced at day 4
(Figs. 3A, B). Importantly, the induction of those proinﬂammatory cy-
tokines was not seen in the MSC-treated group. This in vivo ﬁnding
was reinforced by in vitro assays with freshly isolated peritoneal im-
mune cells. Addition of ischemic brain extracts (IE) to the cell culture
induced the expression of MCP-1 in peritoneal immune cells. This was
blocked by 67% in the presence of MSC-conditioned medium
(Fig. 4A); in contrast, NIH3T3-conditioned medium had only a
minor effect, suggesting that MSCs speciﬁcally secrete anti MCP-1
molecule(s). Likewise, transwell migration assays indicated that the
MCP-1 present in IE was a key chemoattractant for themigration of im-
mune cells (Fig. 4B). The presence of IE in the lower chamber induced
migration of peritoneal immune cells from the upper chamber. MCP-1
(positive control) also induced a similar extent of immune cell migra-
tion. However, these effects were blocked by the presence of cultured
MSCs in the lower chamber (Fig. 4C). Pretreatment of IE with an
anti-MCP-1 neutralizing antibody decreased the immune cell migration
by 65% (Fig. 4B). Collectively, these data suggest that ischemic injury in-
duces MCP-1 to recruit peripheral monocyte/macrophages, and that
soluble factor(s) secreted by MSCs can suppress MCP-1 expression
and the subsequent inﬁltration of peripheral immune cells.
MSC-derived TGF-β1 suppresses MCP-1 expression
MCP-1 is known to be downregulated by immunomodulatory cyto-
kines, such as IL10 (Li and Flavell, 2008) and TGF-β (Wolf et al., 2002). AFig. 3. Suppression of MCP-1 expression by MSCs. (A) RT-PCR analysis of the ischemic
penumbra at day 4 showed induction of MCP-1, iNOS, TNF-α, and IL-1β but not
SDF-1α. PCR products from individual animals injected with PBS or MSCs (n = 3 per
group) are shown. (B) The results shown in (A) were normalized with respect to
GAPDH expression. The data are presented as the mean mRNA levels ± SD compared
to the value obtained from untreated animals before ischemic injury (t-test; *, p b 0.05
and **, p b 0.01).cytokine array analysis indicated that MSCs expressed high levels of
TGF-β but very low levels of IL-10 (Supplementary Fig. S1). Thus, we
tested whether TGF-β mediated the MSC-induced downregulation of
MCP-1. We found that the introduction of an anti-TGF-β neutralizing
antibody negated the suppressive functions of MSC-conditioned medi-
um and restored MCP-1 expression in peripheral immune cells
recruited by simple exposure to IE (Fig. 4A). To further show the
anti-MCP-1 functions of TGF-β1, we knocked down TGF-β1 in MSCs
using a lentiviral vector encoding a TGF-β1-speciﬁc shRNA. Conditioned
medium from TGF-β1-knockdown MSCs (MSCs/shTGF-β1) failed to
suppress MCP-1 expression (Fig. 4D). Furthermore, a TGF-β receptor I
kinase inhibitor (TGF-β-RI) partially restored MCP-1 expression, and
the addition of recombinant TGF-β1 reversed the effect of TGF-β1
knockdown (Fig. 4D). Either anti-TGF-β neutralizing antibody or
TGF-β-RI did not affect the basal MCP-1 expression in the absence of
IE (data not shown). Consistent with these ﬁndings, co-culture of
MSCs/shTGF-β1 in the lower chamber of the transwell apparatus failed
to block the IE-induced migration of immune cells (Fig. 4C). Together,
these data clearly indicate that MSC-secreted TGF-β1 suppresses
MCP-1 expression in inﬂammatory cells.
The therapeutic functions of MSCs are mediated by TGF-β1
To verify the in vivo role of TGF-β1, MSCs/shTGF-β1 were
transplanted into the ischemic penumbra at day 3, when we ob-
served CD68+ macrophages starting to massively inﬁltrate the is-
chemic area through the broken BBB (Fig. 1). Decreased expression
of TGF-β1 inMSCs/shTGF-β1 transplantationwas conﬁrmed through
confocal analysis with hMT and hTGF-β1 speciﬁc antibodies 4 days
after into the ischemic rat brain (Fig. 5A). As we previously reported
(Kim et al., 2008), transplantation of MSCs prevented the inﬁltration
of CD68+ cells at day 7 (Fig. 5B), reduced the infarct volume (34%
and 25% in the control and MSC-treated groups, respectively, on
day 28) (Fig. 5C), and improved the functional recovery from ische-
mic injury (Fig. 5D). In contrast, TGF-β1-knockdown MSCs failed to
prevent the inﬁltration of CD68+ cells into the ischemic area at
day 7 and had only minimal (non-signiﬁcant) effects on infarct vol-
ume and functional recovery (Figs. 5B–D). Collectively, these in
vitro and in vivo ﬁndings indicate that the anti-inﬂammatory func-
tions of MSCs are mediated via TGF-β1 in an animal stroke model.
Discussion
In the present study, we elucidated the molecular mechanisms
underlying the immune modulatory functions of MSCs in an animal
stroke model. We report that MCP-1, a chemoattractant for monocytes/
macrophages, is highly elevated in the ischemic rat brain, where it
induces peripheral immune cells to inﬁltrate into the damaged area
through the impaired BBB. However, MSC-secreted TGF-β1 de-
creases the production ofMCP-1 and attenuates the subsequent inﬁl-
tration of immune cells into the ischemic area.
Microglia, which comprise a major immune cell population in the
central nervous system, occur as Iba1+ cells with ramiﬁed processes
in the resting brain. When activated by brain damage or infection, mi-
croglia increase in number and transform to amoeboid forms with
shorter processes (Benveniste et al., 2001; Hemmer et al., 2002;
Yrjanheikki et al., 1998). Activated microglia secretes a variety of
proinﬂammatory cytokines that are known to aggravate brain inﬂam-
mation. In the ischemic brain, the number of Iba1+ cells with amoe-
boid morphologies greatly increased in number between days 3 and 7
(Fig. 1B). In contrast to observations in chronic brain diseases, most of
the Iba1+ cells that newly emerge in the ischemic area between days
3 and 7 do not appear to be the activated, resident microglia. Instead,
we propose that these cells represent circulatory macrophages that
have inﬁltrated though the impaired BBB. This is supported by several
lines of evidence. Blockage of the blood supply caused massive cell
Fig. 4. MSC-secreted TGF-β1 downregulates MCP-1 expression and attenuates the migration of immune cells. (A) RT-PCR analysis of IE-stimulated peritoneal immune cells in the
presence of conditioned medium (CM) from MSCs or NIH3T3 cells. MSC-CM suppressed MCP-1 expression, and an anti-TGF-β1 antibody reversed this effect. (B) Transwell analysis
with peritoneal immune cells in the upper chamber. The presence of recombinant MCP-1 (rMCP-1) or IE in the lower chamber evoked the migration of immune cells, but the ad-
ditional presence of an anti-MCP-1 neutralizing antibody (α-MCP1) in the lower chamber blocked this migration. (C) MSC-knockdown cells in the lower chamber failed to suppress
the migration of immune cells. The migratory cells (those on the lower side of the membrane) were counted from four random ﬁelds. (D) RT-PCR analysis of peritoneal immune
cells treated with CM from MSCs/shTGF-β1 or MSCs expressing a control scrambled RNA (shScr), with or without 100 nM of recombinant TGF-β1 protein (rTGF-β1) or an inhibitor
of TGF-β1 signaling (TGF-β-RI). MCP-1 mRNA levels were normalized with respect to that of GAPDH. (A–D) Data from at least 3 independent experiments are presented as
means ± SD (t-test; *, p b 0.05 and **, p b 0.01).
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experimental models (Fig. 1D). The repopulation rate of Iba1+/
CD68+ cells was proportional to the extent of BBB breakage (com-
pare Figs. 1A and C). A substantial proportion of the CD68+ cells in
the ischemic area were found to be GFP+ peripheral immune cells
when such cells were exogenously injected into the ischemic animals
(Supplementary Fig. S3). We also observed that MPO+/CD68+ neu-
trophils had inﬁltrated into the ischemic area at day 1 but had
disappeared by day 7 (Supplementary Fig. S4). Our ﬁndings are con-
sistent with previous reports that CD11b+ resident microglia die fol-
lowing lipopolysaccharide injection and brain damage, sequentially
evoking the inﬁltration of neutrophils followed by monocytes/macro-
phages (Ji et al., 2007; Matsumoto et al., 2007). However, our results
could not completely eliminate the possibility that a minor subpopu-
lation of CD68-positive cells were reactive microglia. It is possible that
a subpopulation of the observed CD68+ cells came from the prolifer-
ation or relocation of surviving microglia from adjacent intact brain
areas.
Following ischemia, the recruitment of immune cells toward the
injured area is speciﬁcally guided by chemoattractants, includingMCP-1 and SDF-1. It has been reported that the level of SDF-1β is
markedly enhanced by ischemic stroke, whereas the expression of
SDF-1α remains unchanged (Stumm et al., 2002). Elevated SDF-1β
can recruit exogenously transplanted neuronal progenitor cells
(Imitola et al., 2004) and endogenous neuroblasts newly generated
from the subventricular zone (Thored et al., 2006). Here, we found
that MCP-1 expression was markedly increased by ischemic injury,
whereas SDF-1α expression was unaltered (Fig. 3A). The pathological
role of MCP-1 has been well demonstrated in stroke, and the protein
is known to be upregulated in ischemic stroke patients (Arakelyan et
al., 2005) and animal models (Wang et al., 1995; Yamagami et al.,
1999). Immediately after brain injury, MCP-1 is primarily secreted
by neurons, astrocytes, and microglia (Banisadr et al., 2005). This se-
creted MCP-1 propagates immune responses by recruiting mono-
cytes/macrophages, which subsequently produce more MCP-1. Thus,
increased MCP-1 levels mirror the development of inﬂammatory re-
sponses in vivo. In murine models, genetic ablation of MCP-1
(Hughes et al., 2002) or CCR2 (Dimitrijevic et al., 2007), the primary
receptor for MCP-1, were shown to reduce ischemic infarcts, BBB per-
meability, brain edema, and macrophage inﬁltration.
Fig. 5. Therapeutic effects of MSCs and TGF-β1-knockdown MSCs in a rat model of stroke. (A) Confocal microscopic analysis with an anti-human TGF-β1 antibody (green) and an
anti-humanmitochondria antibody (red) shows that TGF-β1 was persistently decreased in MSCs/shTGF-β1 following transplantation into the ischemic rat brain. (B) CD68+ cells in
the ischemic penumbra of animals treated with PBS, MSCs and MSCs/shTGF-β1 were counted at days 4 and 7. Scale bars in (A) and (B) = 20 μm. (C) The infarct volume was mon-
itored for 28 days with MRI, and is presented as % of the contralateral hemispheric volume. (D) Functional recovery was assessed through adhesive removal and rotarod tests. MSCs
signiﬁcantly improved the functional recovery, but MSCs/shTGF-β1 did not. Data from at least ﬁve animals are presented as means ± SD (ANONA; *, p b 0.05 and **, p b 0.01).
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ﬁltration following ischemia could be prevented by MSC transplanta-
tion. MSC-secreted TGF-β1 could directly suppress the production of
MCP-1 in inﬂammatory cells, impeding the subsequent migration/in-
ﬁltration of macrophages. The presence of an anti-TGF-β1 neutraliz-
ing antibody or an inhibitor of TGF-β1 signaling abolished the
suppressive functions of MSC. When TGF-β1 was depleted, MSCs
could no longer decrease the expression of MCP-1 in immune cells
or attenuate their recruitment to the ischemic area. From this, a
model emerges: Following ischemia, the damaged tissues release
MCP-1, prompting CD68+ cells to inﬁltrate through the impaired
BBB; these cells produce additional MCP-1, leading to the recruitment
of more peripheral immune cells. This vicious cycle of immune prop-
agation, however, can be blocked by MSC-secreted TGF-β1 (Fig. 6).TGF-β1 is a regulatory cytokine that plays pleiotropic roles in the
immune system, where its functions are determined by the pres-
ence of various cytokines at the location of T-cell stimulation
(Becker, 2010). Although early studies suggested that TGF-β has a
proinﬂammatory function in recruiting monocytes (Wahl et al.,
1987), accumulating evidence suggests that TGF-β1 is generally an
anti-inﬂammatory cytokine (Li et al., 2006). In animal stroke
models, depletion of TGF-β1 has been shown to increase inﬂamma-
tory responses (Kulkarni et al., 1993), whereas administration of
TGF-β1 protein or adenoviral transfer of the TGF-β1-encoding
gene reduced the inﬂammatory response via downregulation of
MCP-1 (Pang et al., 2001). Transcription of MCP-1 was regulated
by an AP1 complex composed of a c-jun/c-fos heterodimer (Shyy
et al., 1995) and this AP1-dependent MCP-1 expression was
Fig. 6. Schematic model showing how MSCs interrupt immune propagation in the is-
chemic brain. Ischemic damage sequentially induces MCP-1 expression, massive cell
death of brain cells, and increased BBB permeability. MCP-1 chemoattracts CD68+
monocytes/macrophages from the circulatory blood to the ischemic region through
the impaired BBB. These extravasated C68+ cells produce MCP-1, which induces the
subsequent inﬁltration of more CD68+ cells. Transplanted MSCs downregulate this
MCP-1 expression by secreting TGF-β1, thereby attenuating the inﬁltration of addi-
tional immune cells from the blood. Thus, MSCs interrupt the propagation of immune
responses. Furthermore, MSCs may suppress the production of NO from the extravasat-
ed CD68+ cells through a similar mechanism, and appear to block the inductions of
TNF-α and IL-1β.
256 S.-W. Yoo et al. / Neurobiology of Disease 58 (2013) 249–257suppressed by sequestration of c-jun with Smad3 (Feinberg et al.,
2004). Smad3 is awell-knowndownstream effector of TGF-β1. Targeted
mutation of Smad3 increased the inﬁltration ofMCP-1expressingmacro-
phages following cardiac allografting (Feinberg et al., 2004). Thus, it is
very likely that the anti-inﬂammatory effect of MSCs in this study was
mediated through Smad3 activation by TGF-β1. It should be noted that
the recovery scores (infarct volume, rotarod test, and adhesive removal
tests) of animals treated with TGF-β1-knockdown MSCs were interme-
diate between those of the MSC- and PBS-treated groups (Fig. 6). There-
fore, it is possible that other beneﬁcial factors in addition to TGF-β1, such
as brain-derived neurotrophic factor (BDNF), vascular endothelial
growth factor (VEGF), or nerve growth factor (NGF), may help confer
the full beneﬁts of MSC therapy (Chang et al., 2008; Kinnaird et al.,
2004; Labouyrie et al., 1999; Mahmood et al., 2004).
Stem cell therapy with autograftable MSCs has recently emerged
as a prominent clinical therapy in regenerative medicine. Numerous
studies (including our own) have suggested that the therapeutic ef-
fects of MSCs in animal stroke models arise via the paracrine func-
tions of MSCs rather than their transdifferentiation into neurons
(Caplan and Dennis, 2006; Chopp and Li, 2002; Kim et al., 2008; Yoo
et al., 2008). Recent reports have suggested that MSCs are not only
immune privileged due to their low (or undetectable) expression of
MHC class II, CD40, CD80, and/or CD86 co-stimulatory molecules,
but also (and more importantly) display immune-modulating prop-
erties (Nauta and Fibbe, 2007; Uccelli et al., 2006a). Based on the
immune-modulating property of MSCs, various trials have sought to
use them as a therapeutic agent to block pathogenic immune re-
sponses, such as autoimmune encephalomyelitis (EAE), inﬂammation
after chemical burning of the cornea (Oh et al., 2008; Uccelli et al.,
2006b; Zappia et al., 2005), graft-versus-host diseases (Le Blanc et
al., 2004; Ringden et al., 2006), and Crohn's disease (Duijvestein et
al., 2010). These recent reports have indicated that MSCs and
MSC-secreted factors deﬁnitely interfere with the recruitment of im-
mune cells. However, the mechanisms underlying the immune-
suppressive effects of MSCs have not yet been clearly deﬁned.
In sum, we herein demonstrate that MSCs exert therapeutic effects
by producing TGF-β1 in animal stroke models. Our ﬁndings also sug-
gest that the immune-modulatory functions of MSCs support theirpotential use for the treatment of neurological dysfunctions accompa-
nied by brain inﬂammation. We also propose that transplantation of
MSCs for the treatment of stroke patients may be a more plausible
strategy than administration of anti-inﬂammatory drugs, including
TGF-β1. This is because MSCs can supply additional neurotrophic fac-
tors that protect the neurons from ischemic injury and promote en-
dogenous neurogenesis, while also providing TGF-β1 to make the
brain environment less hostile and allow more time for spontaneous
recovery.
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